For patients with a high recurrence score on the other hand, there was significant improvement of progression free survival independent of the number of positive nodes (hazard ratio 0.59; 95% CI=0.35 1.01).
Nevertheless, despite the improvement of progression-free survival and quality of life, complete remissions after PRRT are still rare.
A high rate of response to EGFR TKIs was indeed found in patients with advanced EGFR-mutant NSCLC resulting in an improvement of progression-free (PFS) and overall (OS) survival of these patients [3].
Looking for prognostic factors, our results suggest that there is a significant improvement of progression-free survival (P=0.05) for those patients who develop severe skin toxicity.
Recently, the combination regimen of everolimus, an mTOR inhibitor, and exemestane, a steroidal AI, was approved for use in this setting based on significant improvement of progression-free survival (PFS) versus exemestane alone [ 4].
For instance, in the first stage of a phase 3 study, obinutuzumab/GA101, a type 2 anti-CD20 antibody glyco-engineered using the same strategy behind GA201, showed improvement of progression-free survival in people with chronic lymphocytic leukaemia (Roche, 2013).
For many years various chemotherapeutic regimen have been applied, either as monochemotherapy or as polychemotherapy, which in general did not result in an improvement of progression-free or overall survival, but sometimes in severe toxicities.
Moreover, besides the expected improvement of progression-free survival obtained by mTOR inhibition in Everolimus-treated patients with endocrine resistant BC, results from the BOLERO-2 trial suggest that this drug significantly delays skeletal disease progression, exerting a definite bone-sparing effect in metastatic BC patients [ 16].
Tyrosine kinase inhibitors (TKIs), e.g. sunitinib and sorafenib, and monoclonal antibodies, e.g. bevacizumab with IFNα, have produced improvements in terms of progression free survival (PFS) and overall survival (OS).
Indeed, when compared to IFN-α, first-line therapy with Sunitinib, Bevacizumab and Temsirolimus showed an improvement of both progression free survival (PFS) and survival.
